Identification of Intraday Metabolic Profiles during Closed-Loop Glucose Control in Individuals with Type 1 Diabetes

Background: Algorithms for closed-loop insulin delivery can be designed and tuned empirically; however, a metabolic model that is predictive of clinical study results can potentially accelerate the process. Methods: Using data from a previously conducted closed-loop insulin delivery study, existing models of meal carbohydrate appearance, insulin pharmacokinetics, and the effect on glucose metabolism were identified for each of the 10 subjects studied. Insulin's effects to increase glucose uptake and decrease endogenous glucose production were described by the Bergman minimal model, and compartmental models were used to describe the pharmacokinetics of subcutaneous insulin absorption and glucose appearance following meals. The composite model, comprised of only five equations and eight parameters, was identified with and without intraday variance in insulin sensitivity (SI ), glucose effectiveness at zero insulin (GEZI), and endogenous glucose production (EGP) at zero insulin. Results: Substantial intraday variation in SI , GEZI and EGP was observed in 7 of 10 subjects (root mean square error in model fit greater than 25 mg/dl with fixed parameters and nadir and/or peak glucose levels differing more than 25 mg/dl from model predictions). With intraday variation in these three parameters, plasma glucose and insulin were well fit by the model (R 2 = 0.933 ± 0.00971 [mean ± standard error of the mean] ranging from 0.879–0.974 for glucose; R 2 = 0.879 ± 0.0151, range 0.819–0.972 for insulin). Once subject parameters were identified, the original study could be reconstructed using only the initial glucose value and basal insulin rate at the time closed loop was initiated together with meal carbohydrate information (glucose, R 2 = 0.900 ± 0.015; insulin delivery, R 2 = 0.640 ± 0.034; and insulin concentration, R 2 = 0.717 ± 0.041). Conclusion: Metabolic models used in developing and comparing closed-loop insulin delivery algorithms will need to explicitly describe intraday variation in metabolic parameters, but the model itself need not be comprised by a large number of compartments or differential equations.

[1]  J. Leahy,et al.  Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas , 2008 .

[2]  M Berman,et al.  A model of the kinetics of insulin in man. , 1974, The Journal of clinical investigation.

[3]  Eldon D Lehmann,et al.  Retrospective pilot feedback survey of 200 users of the AIDA Version 4 Educational Diabetes Program. 1--Quantitative Survey Data. , 2006, Diabetes technology & therapeutics.

[4]  J. Clore,et al.  Morning Insulin Requirements: Critique of Dawn and Meal Phenomena , 1989, Diabetes.

[5]  Y. Z. Ider,et al.  Quantitative estimation of insulin sensitivity. , 1979, The American journal of physiology.

[6]  R. Gabbay,et al.  Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. , 2005, Diabetes technology & therapeutics.

[7]  T. Wolever,et al.  Effect of carbohydrate source on post-prandial blood glucose in subjects with type 1 diabetes treated with insulin lispro. , 2004, Diabetes research and clinical practice.

[8]  N. Draper,et al.  Applied Regression Analysis , 1966 .

[9]  C. Cobelli,et al.  In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes , 2009, Journal of diabetes science and technology.

[10]  R N Bergman,et al.  The Contribution of Insulin-Dependent and Insulin-Independent Glucose Uptake to Intravenous Glucose Tolerance in Healthy Human Subjects , 1994, Diabetes.

[11]  G. Boden,et al.  Evidence for a Circadian Rhythm of Insulin Sensitivity in Patients With NIDDM Caused by Cyclic Changes in Hepatic Glucose Production , 1996, Diabetes.

[12]  F. Ovalle,et al.  Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes , 2009 .

[13]  M Berman,et al.  Modeling the insulin-glucose system in man. , 1974, Federation proceedings.

[14]  Eyal Dassau,et al.  In silico evaluation platform for artificial pancreatic beta-cell development--a dynamic simulator for closed-loop control with hardware-in-the-loop. , 2009, Diabetes technology & therapeutics.

[15]  R. Hovorka,et al.  Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. , 2004, Physiological measurement.

[16]  J Geoffrey Chase,et al.  Model-based insulin and nutrition administration for tight glycaemic control in critical care. , 2007, Current drug delivery.

[17]  Gene F. Franklin,et al.  Digital control of dynamic systems , 1980 .

[18]  John Thomas Sorensen,et al.  A physiologic model of glucose metabolism in man and its use to design and assess improved insulin therapies for diabetes , 1985 .

[19]  G. Steil,et al.  Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy , 2009, Diabetes Care.

[20]  E D Lehmann,et al.  A physiological model of glucose-insulin interaction in type 1 diabetes mellitus. , 1992, Journal of biomedical engineering.

[21]  G. Steil,et al.  Evaluation of the Effect of Gain on the Meal Response of an Automated Closed-Loop Insulin Delivery System , 2006, Diabetes.

[22]  S. Mudaliar,et al.  Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. , 1999, Diabetes care.

[23]  F. Hariri,et al.  Interstitial fluid glucose dynamics during insulin-induced hypoglycaemia , 2005, Diabetologia.

[24]  G. Steil,et al.  Assessment of extracellular glucose distribution and glucose transport activity in conscious rats. , 1995, The American journal of physiology.

[25]  G. Steil,et al.  Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.

[26]  J Geoffrey Chase,et al.  Targeted glycemic reduction in critical care using closed-loop control. , 2005, Diabetes technology & therapeutics.

[27]  Malgorzata E. Wilinska,et al.  Evaluation of glucose controllers in virtual environment: methodology and sample application , 2004, Artif. Intell. Medicine.

[28]  R. Bergman,et al.  Extracellular glucose distribution is not altered by insulin: analysis of plasma and interstitial L-glucose kinetics. , 1996, The American journal of physiology.

[29]  Katsuhiko Ogata,et al.  Modern control engineering (3rd ed.) , 1996 .

[30]  E Salzsieder,et al.  KADIS--a computer-aided decision support system for improving the management of type-I diabetes. , 1990, Experimental and clinical endocrinology.

[31]  R N Bergman,et al.  Assessment of insulin sensitivity in vivo. , 1985, Endocrine reviews.

[32]  G. Steil,et al.  Evaluation of insulin sensitivity and beta-cell function indexes obtained from minimal model analysis of a meal tolerance test. , 2004, Diabetes.

[33]  B De Moor,et al.  An adaptive input–output modeling approach for predicting the glycemia of critically ill patients , 2006, Physiological measurement.

[34]  R. Hovorka,et al.  A simulation model of glucose regulation in the critically ill , 2008, Physiological measurement.

[35]  G. Steil,et al.  Determination of plasma glucose during rapid glucose excursions with a subcutaneous glucose sensor. , 2003, Diabetes technology & therapeutics.

[36]  D. Schade,et al.  The dawn phenomenon revisited: implications for diabetes therapy. , 2005, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[37]  Bart De Moor,et al.  A minimal model for glycemia control in critically ill patients , 2006, 2006 International Conference of the IEEE Engineering in Medicine and Biology Society.

[38]  Jaques Reifman,et al.  Mathematical Modeling Research to Support the Development of Automated Insulin-Delivery Systems , 2009, Journal of diabetes science and technology.

[39]  G Albrecht,et al.  A model-based system for the individual prediction of metabolic responses to improve therapy in type I diabetes. , 1990, Hormone and metabolic research. Supplement series.

[40]  John Fox,et al.  Applied Regression Analysis and Generalized Linear Models , 2008 .

[41]  Michael O'Grady,et al.  Continuous glucose monitoring and intensive treatment of type 1 diabetes. , 2008, The New England journal of medicine.

[42]  G. Steil,et al.  Closed-loop insulin delivery-the path to physiological glucose control. , 2004, Advanced drug delivery reviews.

[43]  G M Steil,et al.  Modeling insulin action for development of a closed-loop artificial pancreas. , 2005, Diabetes technology & therapeutics.

[44]  R N Bergman,et al.  Diurnal Variation in Glucose Tolerance: Cyclic Suppression of Insulin Action and Insulin Secretion in Normal-Weight, But Not Obese, Subjects , 1992, Diabetes.

[45]  William A Petit,et al.  Exaggerated Hyperglycemia After A Pizza Meal in Well-Controlled Diabetes , 1993, Diabetes Care.

[46]  B. Moav,et al.  Thyroid hormone increases transcription of growth hormone mRNA in rainbow trout pituitary. , 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.